Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy

European Journal of Clinical Pharmacology

Volumn 63, Issue 8, 2007, Pages 743-749

  Shirai, Naohito ^a,c   Sugimoto, Mitsushige ^a   Kodaira, Chise ^a   Nishino, Masafumi ^a   Ikuma, Mutsuhiro ^a   Kajimura, Masayoshi ^a,c   Ohashi, Kyoichi ^b   Ishizaki, Takashi ^a   Hishida, Akira ^a   Furuta, Takahisa ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OITA UNIVERSITY   (Japan)

^c Enshu General Hospital   (Japan)

Author keywords

Amoxicillin; CYP2C19; Dual therapy; H. pylori; Metronidazole; Rabeprazole

Indexed keywords

AMOXICILLIN; CARBON 13; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; RABEPRAZOLE; UREA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ERADICATION THERAPY; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UREA BREATH TEST;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METRONIDAZOLE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 34447340220     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0302-8     Document Type: Article

References (56)

1. Blaser MJ (1992) Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology 102(2):720-727
2. Parsonnet J, Blaser MJ, Perez-Perez GI, Hargrett-Bean N, Tauxe RV (1992) Symptoms and risk factors of Helicobacter pylori infection in a cohort of epidemiologists. Gastroenterology 102(1):41-46
3. Uemura N, Okamoto S, Yamamoto S et al (2001) Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345(11):784-789
4. Wotherspoon AC (1998) Helicobacter pylori infection and gastric lymphoma. Br Med Bull 54(1):79-85
5. Malfertheiner P, Megraud F, O'Morain C et al (2002) Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16(2):167-180
6. Furuta T, Shirai N, Takashima M et al (2001) Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 69(3):158-168
7. Lind T, Veldhuyzen van Zanten S, Unge P et al (1996) Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1(3):138-144
8. Asaka M, Sugiyama T, Kato M et al (2001) A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 6(3):254-261
9. Kim JM, Kim JS, Jung HC, Kim N, Kim YJ, Song IS (2004) Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother 48(12):4843-4847
10. Matsuhisa T, Kawai T, Masaoka T et al (2006) Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori infection in the Japanese population: a multicenter study in the Tokyo Metropolitan Area. Helicobacter 11(3):152-158
11. Nagahara A, Miwa H, Kawabe M et al (2004) Second-line treatment for Helicobacter pylori infection in Japan: proton pump inhibitor-based amoxicillin and metronidazole regimen. J Gastroenterol 39(11):1051-1055
12. Murakami K, Sato R, Okimoto T et al (2003) Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment Pharmacol Ther 17(1):119-123
13. Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori (1992) European Study Group on Antibiotic Susceptibility of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 11(9):777-781
14. Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W (1998) Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin-influence on treatment outcome. Am J Gastroenterol 93(3):386-389
15. Megraud F, Doermann HP (1998) Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. Gut 43(Suppl 1):S61-S65
16. Debets-Ossenkopp YJ, Herscheid AJ, Pot RG, Kuipers EJ, Kusters JG, Vandenbroucke-Grauls CM (1999) Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother 43(4):511-515
17. Parsons HK, Carter MJ, Sanders DS, Winstanley T, Lobo AJ (2001) Helicobacter pylori antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic status. Aliment Pharmacol Ther 15(9):1473-1478
18. Beard CM, Noller KL, O'Fallon WM, Kurland LT, Dahlin DC (1988) Cancer after exposure to metronidazole. Mayo Clin Proc 63(2):147-153
19. Cavaliere A, Bacci M, Amorosi A, Del Gaudio M, Vitali R (1983) Induction of lung tumors and lymphomas in BALB/c mice by metronidazole. Tumori 69(5):379-382
20. Beard CM, Noller KL, O'Fallon WM, Kurland LT, Dockerty MB (1979) Lack of evidence for cancer due to use of metronidazole. N Engl J Med 301(10):519-522
21. Friedman GD, Selby JV (1989) Metronidazole and cancer. JAMA 261(6):866
22. Furuta T, Ohashi K, Kamata T et al (1998) Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 129(12):1027-1030
23. Furuta T, Ohashi K, Kosuge K et al (1999) CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 65(5):552-561
24. Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T (2001) Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 70(5):484-492
25. Sugimoto M, Furuta T, Shirai N et al (2004) Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 76(4):290-301
26. Furuta T, Shirai N, Takashima M et al (2001) Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 11(4):341-348
27. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T (2003) Retreatment of H. pylori with dual therapy using high doses of rabeprazole or lansoprazole can be effective. Aliment Pharmacol Ther 18(11-12):1175-1176
28. Furuta T, Shirai N, Xiao F et al (2003) High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology 50(54):2274-2278
29. Furuta T, Sagehashi Y, Shirai N et al (2005) Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. Clin Gastroenterol Hepatol 3(6):564-573
30. Dent JC, McNulty CA (1988) Evaluation of a new selective medium for Campylobacter pylori. Eur J Clin Microbiol Infect Dis 7(4):555-558
31. Clayton CL, Kleanthous H, Coates PJ, Morgan DD, Tabaqchali S (1992) Sensitive detection of Helicobacter pylori by using polymerase chain reaction. J Clin Microbiol 30(1):192-200
32. Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W (1998) Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin-influence on treatment outcome. Am J Gastroenterol 93(3):386-389
33. Kato M, Asaka M, Ohara S, Toyota T (1998) Clinical studies of 13C-urea breath test in Japan. J Gastroenterol 33(Suppl)10:36-39
34. Vakil N, Hahn B, McSorley D (1998) Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol 93(9):1432-1435
35. Murakami K, Fujioka T, Okimoto T, Sato R, Kodama M, Nasu M (2002) Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int J Antimicrob Agents 19(1):67-70
36. Wurzer H, Rodrigo L, Stamler D et al (1997) Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. Aliment Pharmacol Ther 11(5):943-952
37. Gisbert JP, Pajares JM (2002) Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 16(6):1047-1057
38. Labenz J, Stolte M, Blum AL et al (1995) Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut 37(1):39-43
39. Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC, Jr (1989) Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 8(10):888-889
40. Athamna A, Athamna M, Medlej B, Bast DJ, Rubinstein E (2004) In vitro post-antibiotic effect of fluoroquinolones, macrolides, beta-lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin/dalfopristin and rifampicin on Bacillus anthracis. J Antimicrob Chemother 53(4):609-615
41. Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM (2006) Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther 24(10):1469-1474
42. Borody TJ, Pang G, Wettstein AR et al (2006) Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. Aliment Pharmacol Ther 23(4):481-488
43. Isakov V, Domareva I, Koudryavtseva L, Maev I, Ganskaya Z (2002) Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole. Aliment Pharmacol Ther 16(7):1277-1282
44. Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T (1992) Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther 262(3):1195-1202
45. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T, Ishizaki T (1993) Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther 266(1):52-59
46. Ishizaki T, Sohn DR, Kobayashi K et al (1994) Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit 16(2):214-215
47. Chang M, Tybring G, Dahl ML et al (1995) Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 39(5):511-518
48. Ieiri I, Kubota T, Urae A et al (1996) Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 59(6):647-653
49. Shirai N, Furuta T, Moriyama Y et al (2001) Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 15(12):1929-1937
50. Shirai N, Furuta T, Xiao F et al (2002) Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups. Aliment Pharmacol Ther 16(4):837-846
51. Yasuda S, Horai Y, Tomono Y et al (1995) Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther 58(2):143-154
52. Ishizaki T, Horai Y (1999) Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 13(Suppl 3):27-36
53. Williams MP, Sercombe J, Hamilton MI, Pounder RE (1998) A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 12(11):1079-1089
54. Stedman CA, Barclay ML (2000) Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 14(8):963-978
55. Furuta T, Shirai N, Xiao F et al (2004) Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy. Clin Gastroenterol Hepatol 2(1):22-30
56. Kubota T, Chiba K, Ishizaki T (1996) Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 60(6):661-666